Your browser is no longer supported. Please, upgrade your browser.
EYPT EyePoint Pharmaceuticals, Inc. daily Stock Chart
EYPT [NASD]
EyePoint Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.50% Shs Outstand145.38M Perf Week-20.22%
Market Cap206.44M Forward P/E- EPS next Y-0.28 Insider Trans1.39% Shs Float107.32M Perf Month-28.64%
Income-58.00M PEG- EPS next Q-0.12 Inst Own58.20% Short Float7.49% Perf Quarter0.00%
Sales14.20M P/S14.54 EPS this Y54.30% Inst Trans1.47% Short Ratio12.82 Perf Half Y-5.96%
Book/sh0.15 P/B9.47 EPS next Y50.00% ROA-70.20% Target Price4.33 Perf Year-47.79%
Cash/sh0.22 P/C6.49 EPS next 5Y- ROE-228.10% 52W Range1.19 - 2.75 Perf YTD-8.39%
Dividend- P/FCF- EPS past 5Y-1.60% ROI-44.50% 52W High-50.91% Beta1.54
Dividend %- Quick Ratio4.30 Sales past 5Y-3.40% Gross Margin90.40% 52W Low13.45% ATR0.16
Employees55 Current Ratio4.50 Sales Q/Q400.00% Oper. Margin- RSI (14)31.42 Volatility6.00% 6.82%
OptionableYes Debt/Eq2.94 EPS Q/Q66.80% Profit Margin- Rel Volume2.18 Prev Close1.42
ShortableYes LT Debt/Eq2.94 EarningsMar 05 BMO Payout- Avg Volume626.69K Price1.35
Recom2.00 SMA20-27.47% SMA50-19.52% SMA200-19.51% Volume725,282 Change-4.93%
Nov-04-19Resumed Laidlaw Buy $5
Sep-12-19Initiated Guggenheim Buy
Feb-21-20 09:09AM  EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -25.64%
07:46AM  The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 04:01PM  EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-18-20 07:00AM  EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU® GlobeNewswire
Feb-04-20 07:51AM  The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares Benzinga
Feb-03-20 05:24PM  EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion GlobeNewswire
Jan-30-20 07:56AM  Will EyePoint Continue to Surge Higher? Zacks
Jan-27-20 07:00AM  EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan GlobeNewswire
Jan-23-20 07:00AM  EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues GlobeNewswire +23.60%
Dec-22-19 05:31PM  EyePoint Pharmaceuticals, Inc. (EYPT): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-04-19 07:00AM  EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S. GlobeNewswire
Nov-25-19 06:46PM  Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-19-19 10:54AM  EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility GlobeNewswire
Nov-14-19 07:00AM  EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development GlobeNewswire
Nov-07-19 07:30AM  EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates Zacks -28.14%
06:00AM  EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress GlobeNewswire
Nov-04-19 07:00AM  EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule GlobeNewswire
Nov-01-19 07:00AM  EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® GlobeNewswire
Oct-31-19 10:35AM  Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-24-19 07:00AM  EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information GlobeNewswire
Oct-02-19 04:05PM  EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect GlobeNewswire
Sep-27-19 07:00AM  EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting GlobeNewswire
Sep-26-19 07:00AM  EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire -6.49%
Sep-09-19 07:00AM  EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting GlobeNewswire
Sep-06-19 08:32AM  Edited Transcript of EYPT earnings conference call or presentation 7-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-23-19 11:24AM  Keep Your Eye on These 4 Healthcare Stocks Motley Fool
Aug-07-19 07:35AM  EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates Zacks +14.29%
06:00AM  EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
Jul-31-19 10:36AM  EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
07:06AM  The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster Benzinga
Jul-30-19 04:15PM  EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists GlobeNewswire
Jul-25-19 07:00AM  EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) GlobeNewswire
Jul-24-19 07:00AM  EyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information GlobeNewswire
Jul-23-19 07:00AM  EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists GlobeNewswire
Jul-15-19 07:00AM  EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors GlobeNewswire
Jul-08-19 09:13AM  EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% PR Newswire
Jul-01-19 07:00AM  EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes GlobeNewswire
Jun-29-19 05:26PM  Hedge Funds Have Never Been This Bullish On EyePoint Pharmaceuticals, Inc. (EYPT) Insider Monkey
Jun-13-19 07:00AM  EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-10-19 07:00AM  EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires GlobeNewswire
May-17-19 04:39AM  Edited Transcript of EYPT earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-15-19 07:00AM  EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
May-08-19 07:30AM  EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:13AM  EyePoint Pharmaceuticals: 1Q Earnings Snapshot Associated Press
06:00AM  EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
May-01-19 10:32AM  Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know Zacks
07:00AM  EyePoint Pharmaceuticals Presents Positive YUTIQ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire
Apr-23-19 07:00AM  EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information GlobeNewswire
Apr-16-19 07:00AM  EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences GlobeNewswire
Apr-02-19 07:00AM  EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire +6.82%
Mar-28-19 12:44PM  Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today Motley Fool -19.91%
09:11AM  EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Mar-27-19 04:05PM  EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-20-19 12:18PM  Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
Mar-14-19 04:35PM  EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript Motley Fool -5.02%
09:30AM  EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:25AM  EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot Associated Press
06:00AM  EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments GlobeNewswire
Mar-13-19 07:27AM  The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie Benzinga
Mar-12-19 04:15PM  EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9% GlobeNewswire
Feb-14-19 07:00AM  EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information GlobeNewswire
Feb-13-19 04:15PM  EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility GlobeNewswire
Feb-04-19 07:00AM  EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg GlobeNewswire
Jan-30-19 10:31AM  Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline Zacks
Jan-28-19 07:00AM  EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors GlobeNewswire -5.79%
Jan-03-19 10:35AM  4 Pharma Stocks Raising Eyebrows (1/3/19) ACCESSWIRE
07:00AM  EyePoint Pharmaceuticals Provides 2019 Commercial Update GlobeNewswire
Dec-17-18 04:23PM  EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index GlobeNewswire
Nov-29-18 08:46AM  Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options Zacks +9.71%
Nov-27-18 04:05PM  EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary GlobeNewswire
Nov-12-18 07:00AM  EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU by the Center for Medicare and Medicaid Services (CMS) GlobeNewswire -6.52%
Nov-06-18 04:10PM  EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
07:30AM  EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:04AM  The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering Benzinga
06:22AM  EyePoint Pharmaceuticals: Fiscal 1Q Earnings Snapshot Associated Press
06:00AM  EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments GlobeNewswire
Nov-05-18 04:11PM  EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region GlobeNewswire -6.48%
Oct-30-18 07:30AM  EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information GlobeNewswire +7.00%
07:00AM  EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors GlobeNewswire
Oct-29-18 07:00AM  EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting GlobeNewswire -9.91%
Oct-18-18 07:00AM  EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting GlobeNewswire
Oct-17-18 11:42AM  EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq Zacks -5.97%
Oct-16-18 08:54AM  EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8% Zacks -7.83%
Oct-15-18 12:37PM  Stock Market News Daily Roundup October 15 Market Exclusive +6.81%
07:38AM  EyePoint Pharma shares jump on FDA approval of Yutiq implant MarketWatch
06:30AM  EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg GlobeNewswire
Oct-01-18 10:13AM  Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options Zacks
07:00AM  EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants GlobeNewswire
Sep-12-18 03:58PM  US Stocks Lower on Wednesday GuruFocus.com
07:35AM  EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:36AM  EyePoint Pharmaceuticals: Fiscal 4Q Earnings Snapshot Associated Press
06:00AM  EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress GlobeNewswire
Sep-10-18 07:00AM  EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors GlobeNewswire
Sep-06-18 10:45AM  Healthcare Stocks Take Center Stage In September ACCESSWIRE +9.43%
08:28AM  The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data Benzinga
Sep-05-18 04:15PM  EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU GlobeNewswire
07:00AM  EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information GlobeNewswire
Sep-03-18 10:34AM  EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release Zacks
Aug-28-18 07:00AM  EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Aug-15-18 07:00AM  EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality GlobeNewswire
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elston GeorgeChief Financial OfficerNov 15Buy1.4310,00014,29010,000Nov 18 08:42 AM